Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Veritas In Silico tumbles for first time in 3 sessions after ending joint drug discovery research with Takeda◇
Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Takeda Announces Candidates for Board of Directors and Change in Representative Director at Upcoming Shareholders Meeting
Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
Takeda Announces U.S. FDA Accepts NDA and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
U.S. FDA Accepts NDA and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepy Type 1
Earnings Report (Kessan Tanshin) for the Nine-month Period Ended December 31, 2025 (IFRS, Consolidated)
Takeda Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 1%
Takeda’s Zasocitinib Landmark Ph3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in PV
The 149th (interim period) Business Report
Semi-annual Securities Report (The semi-annual of 149th Business Term) for The Six-month Period Ended September 30, 2025
Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2025 (IFRS, Consolidated)
Takeda Pharma, Net Income Forecast for the Fiscal Year Revised Downward by 33%
Takeda Provides Update on Cell Therapy Research
Information About General Reserve and Other Voluntary Reserves
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
Statement on Inadvertent Abstract Disclosure for Opevorexton (TAK-861) by World Sleep Congress
Takeda Pharma, Apr-Jun (1Q) Net Income Increases by 30%